The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel
Official Title: An Open-Label, Phase I/Ib Dose Escalation Study to Assess the Safety and Tolerability of GSK1120212 in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Study ID: NCT01192165
Brief Summary: The purpose of this study is to determine what dose of GSK1120212 can be given safely in combination with at least one other drug that is already approved to treat cancer. This study will test the safety of up to 6 different GSK1120212 study treatment combinations (GSK1120212 plus either docetaxel, erlotinib, pemetrexed, pemetrexed + carboplatin, pemetrexed + cisplatin, or nab-paclitaxel). The doses identified in this study may be used in future trials to test whether the combination treatment is a safe and effective therapy for subjects with metastatic lung and/or pancreatic cancers.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
GSK Investigational Site, Scottsdale, Arizona, United States
GSK Investigational Site, Duarte, California, United States
GSK Investigational Site, Sacramento, California, United States
GSK Investigational Site, Denver, Colorado, United States
GSK Investigational Site, Las Vegas, Nevada, United States
GSK Investigational Site, Albany, New York, United States
GSK Investigational Site, Greenville, South Carolina, United States
GSK Investigational Site, Nashville, Tennessee, United States
GSK Investigational Site, Dallas, Texas, United States
GSK Investigational Site, Houston, Texas, United States
GSK Investigational Site, Tyler, Texas, United States
GSK Investigational Site, Norfolk, Virginia, United States
GSK Investigational Site, Vancouver, Washington, United States
GSK Investigational Site, Toronto, Ontario, Canada
GSK Investigational Site, Caen Cedex 9, , France
GSK Investigational Site, Marseille cedex 5, , France
GSK Investigational Site, Saint-Herblain cedex, , France
GSK Investigational Site, Toulouse cedex, , France
GSK Investigational Site, Seoul, , Korea, Republic of
GSK Investigational Site, Seoul, , Korea, Republic of
Name: GSK Clinical Trials
Affiliation: GlaxoSmithKline
Role: STUDY_DIRECTOR